

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)




(10) International Publication Number
WO 2023/076243 A1

- (51) **International Patent Classification:**
A61K 31/4995 (2006.01) *A61K 45/06* (2006.01)
A61K 31/38 (2006.01) *A61P 1/16* (2006.01)
- (21) **International Application Number:**
PCT/US2022/047694
- (22) **International Filing Date:**
25 October 2022 (25.10.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/271,916 26 October 2021 (26.10.2021) US
63/280,470 17 November 2021 (17.11.2021) US
63/354,424 22 June 2022 (22.06.2022) US
- (71) **Applicant: MIRUM PHARMACEUTICALS, INC.**
[US/US]; 950 Tower Lane, Suite 1050, Foster City, CA
94404 (US).
- (72) **Inventor: PEETZ, Christopher;** c/o Mirum Pharmaceuticals, Inc., 950 Tower Lane, Suite 1050, Foster City, CA
94404 (US).
- (74) **Agent: KHANKIN, Alina K.** et al.; Troutman Pepper
Hamilton Sanders LLP, 875 Third Avenue, 17th Floor, New
York, NY 10022 (US).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) **Title:** METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs)

FIGURE 1



(57) **Abstract:** The present invention relates generally to methods for reducing, minimizing, preventing, ameliorating, or eliminating one or more side effects associated with administration of an apical sodium-dependent bile acid transporter inhibitor (ASBTI). The present invention relates also to methods of treating cholestatic liver disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of an ASBTI to the subject before ingestion of food.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))